Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis

Giaccone, Giuseppe; Bagatella, M; Donadio, Michela; Bonardi, Gianmaria; Maestroni, Franco; Calciati, A

doi:10.1177/030089168907500112

Tumori

1989

DOI: 10.1177/030089168907500112

|View full text |Cite

Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis

Giuseppe Giaccone

M Bagatella

Michela Donadio

et al.

Abstract: No clear evidence of survival benefit has been definitely shown by chemotherapy in advanced non-small-cell lung cancer. We evaluated in a randomized trial the activity of the new drug lonidamine (up to 1050 mg/day) versus MVP (mitomycin C, 10 mg/m2, vinblastine, 5 mg/m2, cisplatin, 100 mg/m2). The preliminary findings on 25 patients showed that lonidamine can be easily administered at these dose ranges, and main toxicity was represented by myalgia and testicular pain. Tolerance to combination chemotherapy (MVP… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1990

1995

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

Buccheri¹,

Ferrigno²,

Rosso³

1993

Cancer

View full text Add to dashboard Cite

Background. Combination chemotherapy with conventional antiproliferative drugs is becoming the treatment of choice for patients with advanced non‐small cell lung cancer (NSCLC), a good performance status, and no major clinical contraindications. Lonidamine (LND), a new drug with an innovative mechanism of action, might potentiate anticancer activity, without increasing toxicity. Methods. In a Phase II study, 46 patients with advanced NSCLC were assigned to receive chemotherapy with the methotrexate, doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), cyclophosphamide, and lomustine (MACC) regimen, as originally described, plus LND, 150 mg orally, three times per day. Treatment was continued until progression of disease, occurrence of unacceptable toxic effects, or refusal by the patient (the median duration of MACC treatment was 6 weeks; 7 weeks for LND). Results. For the whole group of patients, actual dose intensities (DI) of MACC and LND were 95% and 67% of those projected (median values), respectively. There was a negative correlation between duration of chemotherapy and the DI of MACC reached in each patient. On the contrary, there was no correlation between the duration of treatment with LND and its DI. The DI of LND and MACC were not correlated with each other. In all, seven objective responses (only partial responses) were observed. The overall median survival time was 42 weeks (confidence limits [CL], 20–52). The median survival length of patients receiving the full dose of LND (450 mg daily for at least 1 week) was 46 weeks (CL, 28–67), as compared with the median survival of 19 weeks (lower CL, 9 weeks) for the remaining patients; this difference was statistically significant (P ± 0.05, Breslow test). Toxic effects were as expected with the use of MACC. They were mainly gastrointestinal (any grade of toxicity occurring in 64% of the patients), hematologic (anemia, 44%; leukopenia, 36%; thrombocytopenia, 8%), oral (25%), renal (14%), and cardiac (11%). There was only one treatment‐related death, from myocardial infarction and neutropenic sepsis. Uncommon side effects, which were attributed to LND, were mild to moderate and reversible; they included myalgia (26%), asthenia (15%), testicle pain (11%), visual problems (7%), and gastric intolerance (7%). Conclusions. MACC plus LND is a moderately active regimen in advanced NSCLC, with foreseeable and reversible toxic effects of low–medium grade. Potential enhancements of antitumor activity and possible host survival benefits may be expected by the addition of LND to MACC, but a Phase III study must be performed to identify them.

show abstract

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

Buccheri¹,

Ferrigno²,

Rosso³

1993

Cancer

View full text Add to dashboard Cite

show abstract

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer

Buccheri

Ferrigno

1994

European Journal of Cancer

View full text Add to dashboard Cite

A Phase II Study on Lonidamine Combined with Cisplatin and Etoposide in the Treatment of Advanced Non-Small Cell Bronchogenic Carcinoma (NSCBC)

Lelli¹,

Guaraldi²,

Canova³

et al. 1990

Journal of Chemotherapy

View full text Add to dashboard Cite

A group of 28 patients with advanced non-small cell bronchogenic carcinoma (NSCBC) entered a phase II study on cisplatin (60 mg/m2, day 1) plus etoposide 120 mg/m2, day 1 to 3), every 3 weeks, in combination with lonidamine (150 mg p.o. t.i.d. continuously from day 1). Seven out of twenty-seven (26%) evaluable patients obtained a partial remission (median duration 22 weeks, range 7-47). Although the side effects were mild, three patients stopped the therapy because of them. Median survival was 14 months, range 2-19. Further studies are necessary to clarify the role of "biochemical modulators" in NSCBC.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis

Cited by 5 publications

References 9 publications

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer

A Phase II Study on Lonidamine Combined with Cisplatin and Etoposide in the Treatment of Advanced Non-Small Cell Bronchogenic Carcinoma (NSCBC)

Contact Info

Product

Resources

About